Mutations or deletions in the CDKN2A gene can lead to the loss of function of its encoded proteins, p16INK4a and p14ARF. This loss of function disrupts cell cycle control and allows cells to proliferate uncontrollably, contributing to the development and progression of cancer. Such mutations are frequently observed in various cancers, including melanoma, pancreatic cancer, and glioblastoma.
